Dr. Emiliano Calvo Leads the Discussion of Next Generation Immunotherapy at ASCO 2023
2023 ASCO – Next Generation Immunotherapy Congratulations to Dr. Emiliano Calvo, Director of START Spain, for leading the discussion of Next Generation Immunotherapy agents on June 4th during the ASCO annual meeting. read Linked Post Here
Dr. Emiliano Calvo Leads the Discussion of Next Generation Immunotherapy at ASCO 2023 Read More »
START Center Principal Investigators Contributed As Authors to 10 Posters and Abstracts at the Annual ESMO IO Meeting
2022 ESMO IMMUNO-ONCOLOGY (ESMO IO) ACTIVITY SUMMARY The START Center investigators contributed as authors to posters and abstracts at this year’s ESMO IO meeting in Geneva, Switzerland. Congratulations to the START physician team, Dr. Kyriakos Papadopoulos, Dr. Nehal Lakhani, Dr. Manish Sharma, Dr. Amita Patnaik, Dr. Drew Rasco, and Dr. Victor Moreno, for their contributions
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase I Trial Evaluating XL102 in Patients with Advanced Solid Tumors
Download Announcement ALAMEDA, Calif.–(BUSINESS WIRE)–Dec. 8, 2022– Exelixis, Inc. (Nasdaq: EXEL) today announced initial results from the ongoing dose-escalation stage of QUARTZ-101, a phase 1 clinical trial evaluating XL102, a potent, selective, irreversible and orally bioavailable small molecule cyclindependent kinase 7 (CDK7) inhibitor, in patients with advanced solid tumors. The data are being presented on
START Center for Cancer Care to Open New Locations in Lisbon and Dublin
First oncology early-phase clinical trials units in Portugal and Ireland to offer leading-edge cancer treatments –(BUSINESS WIRE)– SAN ANTONIO–(BUSINESS WIRE)–The START Center for Cancer Care, a San Antonio-based oncology early-phase clinical research site network, will open Portugal’s first facility in Lisbon in late 2022 and is slated to open Ireland’s first early-phase clinical research facility
START Center for Cancer Care to Open New Locations in Lisbon and Dublin Read More »
